Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis
暂无分享,去创建一个
Chul-woo Yang | S. Kim | J. Do | K. Joo | Y. Kim | Yong-Lim Kim | J. S. Lee | K. Na | S. Shin | Su-Kil Park | Seungyeup Han | J. H. Lee | W. An | G. Kang | Byung Ha Chung | G. Shin | B. Shin | K. Lee
[1] E. Hodson,et al. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. , 2016, The Cochrane database of systematic reviews.
[2] K. Kitamura,et al. Effects of uroguanylin on natriuresis in experimental nephrotic rats , 2009, Nephrology.
[3] J. J. de la Cruz,et al. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. , 2008, Kidney international. Supplement.
[4] C. Stehman-Breen,et al. An open‐label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis , 2006, Journal of internal medicine.
[5] D. Scarlata,et al. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. , 2006, Mayo Clinic proceedings.
[6] D. Scarlata,et al. Darbepoetin alfa Administered Every Other Week Maintains Hemoglobin Levels over 52 Weeks in Patients with Chronic Kidney Disease Converting from Once-Weekly Recombinant Human Erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR) , 2006, American Journal of Nephrology.
[7] R. Toto,et al. Darbepoetin Alfa Effectively Treats Anemia in Patients with Chronic Kidney Disease with de novo Every-Other-Week Administration , 2004, American Journal of Nephrology.
[8] A. Collins,et al. New epoetin molecules and novel therapeutic approaches. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] Patty Downey. Recombinant Human Erythropoietin as a Treatment for Anemia of Prematurity , 1997, The Journal of perinatal & neonatal nursing.
[10] David C. Murray,et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] M. Rudnick,et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] Paganini Ep. Overview of anemia associated with chronic renal disease: primary and secondary mechanisms. , 1989 .
[13] E. Paganini. Overview of anemia associated with chronic renal disease: primary and secondary mechanisms. , 1989, Seminars in nephrology.